Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol ED50 with different esketamine doses for BlockBuster LMA insertion in intestinal polypectomy
ChiCTR2600124046Phase 4Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of propofol and esketamine in intestinal polyp (4 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: ED50 and ED95 of propofol dose for successful BlockBuster laryngeal mask insertion. Started May 2026; status: recruiting.
02
Drugs
propofolesketamine
03
Conditions
intestinal polyp
Beyond the preview
Go deeper on ChiCTR2600124046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124046.